SCHEMBL2409353

SCHEMBL2409353

CC(NC(=O)Nc1cccc(C(F)(F)F)c1)c1ccc(C(=O)NO)s1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.58
KDM4E B2RXH2 1/20 0.58
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
HTT P42858 3/20 0.55
LMNA P02545 3/20 0.55
POLB P06746 1/20 0.55
MAPT P10636 6/20 0.55
TP53 P04637 4/20 0.55
RAB9A P51151 1/20 0.50
ALDH1A1 P00352 1/20 0.49
DGAT1 O75907 1/20 0.47
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
MAPK1 P28482 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404440 0.86 EPHX2 (0.49) MEN1KMT2AHTTMAPTRAB9A
SCHEMBL2406944 0.84 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AMAPTTP53
SCHEMBL12271271 0.82 HSD17B10 (0.56) SMN1; SMN2HTTTP53RAB9A
SCHEMBL2406913 0.82 KDR (0.43) MEN1KMT2ACA12CA1CA2
SCHEMBL2406864 0.82 KDR (0.56) LMNAMAPTGAACA1CA2
SCHEMBL2409476 0.81 CA12 (0.43) LMNAMAPTTP53ALDH1A1GAA
SCHEMBL2408579 0.80 SMN1; SMN2 (0.63) SMN1; SMN2KDM4EMEN1KMT2AHTT
SCHEMBL2410703 0.78 HDAC3 (0.50) SMN1; SMN2MEN1KMT2AHTTLMNA
SCHEMBL2405524 0.78 TSHR (0.51) SMN1; SMN2KMT2APOLBMAPTTP53
SCHEMBL2406688 0.78 RAB9A (0.47) SMN1; SMN2KDM4EMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9227951-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-01-05 US disclosed
US-9227951-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-01-05 US disclosed
US-20140228416-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-14 US disclosed
US-20140228416-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-14 US disclosed
US-8546588-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-10-01 US disclosed
WO-2011106627-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed
US-20110213003-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110213003-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213003-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC3 SMN1; SMN2 852/4885KDM4E 756/4885MEN1 3939/4885
US-20140228416-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC3 SMN1; SMN2 852/4885KDM4E 756/4885MEN1 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.